Most recently, Hiller has served as the CEO of venture-backed cardiovascular device start-up Heartscape Technologies.
Prior to that he worked as the senior vice president at Millennium Pharmaceuticals.
Hiller said the patented SciFluor technology offers companies a solution to the challenge of fluorination that has the potential to significantly accelerate and improve the drug discovery and development process.
"The platform also gives SciFluor an opportunity to identify fluorinated versions of currently marketed products that may support partnerships with drug companies and ultimately offer physicians and their patients new and enhanced treatment options," Hiller said.